Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
From 2013 an annual nasal live-attenuated influenza vaccine (LAIV—Fluenz) is available for all children in the UK aged 2 and 3 years and other ‘at-risk’ children, as part of the National Health Service (NHS) childhood vaccination programme.1 ,2 The vaccine contains reassortant influenza viruses; two influenza A viruses (H1N1 and H3N2) and one influenza B virus,3 and has previously been used in children in the USA.
A 2-year-old child presented with respiratory symptoms. PCR assay of nasopharyngeal swab was strongly positive for Rhinovirus (Cycle Threshold, CT 21) and weakly positive for Influenza B (CT 37.6). Further questioning revealed that the child had received the intranasal influenza vaccine 10 days previously. Due to the difference in CT values and detection of an alternative virus (Rhinovirus), a diagnosis of Rhinovirus bronchiolitis was made and the weak Influenza B positivity was attributed to the intranasal vaccine.
Immunocompetent children vaccinated with LAIV can shed vaccine viruses for up to 3 weeks (mean duration: 7.6 days); maximal shedding occurs within 2 days of vaccination. Shedding is in lower amounts than with wild-type influenza viruses. Rarely, shed vaccine viruses can be transmitted from vaccine recipients to unvaccinated persons; however, serious illness has not been reported.4
Both wild-type and live-attenuated vaccine virus strains are detected by laboratory respiratory PCR assay. Wild-type and vaccine virus strains could be distinguished by genome sequencing; however, the low copy number of shed vaccine virus precludes this approach. In this case, a clinical decision must be made as to whether the influenza virus is the cause of disease or a consequence of vaccination. This will influence decisions about treating with antivirals.
As LAIV is introduced into UK clinical practice, this is a useful reminder to take care in interpreting respiratory PCR results in recently vaccinated children, highlighting the need for a precise vaccination history.
Contributors SL and CA prepared the manuscript and TH reviewed.
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.